* Sarepta therapeutics announces fda accelerated approval of
exondys 51(tm) (eteplirsen) injection, an exon skipping therapy
to treat duchenne muscular dystrophy (dmd) patients amenable to
skipping…
The post BRIEF-Sarepta Therapeutics says U.S. Commercial launch for Exondys 51 planned to commence immediately appeared first on NASDAQ.